Subscribe to access the full database, or Start Trial
Tradename	Generic Name
STOXIL	idoxuridine
DENDRID	idoxuridine
HERPLEX	idoxuridine
DENAVIR	penciclovir
PENCICLOVIR	penciclovir
>Tradename	>Generic Name

Last updated: June 9, 2026

ATC Class D06BB (“Antivirals”) covers topical antiviral medicines, primarily for skin viral infections. The patent landscape is fragmented by active ingredient, route (topical), and formulation vehicle (cream/gel/solution), with periodic waves of patent expiry driving generic or “therapeutic equivalent” competition. Market dynamics are shaped by (1) narrow therapeutic indications, (2) dosing frequency and vehicle constraints, (3) limited payer formularies versus systemic antivirals, and (4) long-tail IP anchored in formulation, delivery systems, and method-of-use rather than purely drug-substance claims.

Which patents protect ATC D06BB antivirals, and how broad is the estate?

Answer: Patent protection in D06BB typically concentrates in three clusters: (1) specific drug substances or isomers (where new chemical entities exist), (2) topical formulations with defined rheology, concentrations, excipients, and pH targets, and (3) medical-use claims tied to treating specific viral conditions (for example, herpes labialis, herpes genitalis, or viral skin lesions). The estate is rarely “one big backbone patent”; it is usually a bundle of weak-to-moderate patents across jurisdictions.

Common patent claim buckets seen in D06BB topical antivirals

Drug substance and salt/isomer scope

Coverage can extend if the active ingredient is not purely generic or if there are prodrugs/salts, specific polymorphs, or isomeric forms.
In many markets, older antivirals already moved off-patent, leaving formulation and use patents as the main barriers.

Formulation and vehicle patents

Topical antivirals often have dense IP around:

Concentration ranges (wt% APIs)
Solvent system (alcohol/water ratios), pH setpoints, and buffering systems
Polymer choices for gels/creams that govern skin residence time
Stabilizers that prevent API degradation (light/oxidation/hydrolysis)
Packaging and delivery constraints (where claimed as part of the invention)

Method-of-use patents

Claims often recite a treatment regimen: frequency, duration, and patient population.
Method-of-use can remain enforceable even when the molecule is generic, though enforceability and claim scope depend on jurisdiction and litigation posture.

Which D06BB actives tend to have enforceable IP longer?

Answer: In practice, D06BB estates persist where a company filed newer formulation or skin-delivery patents or where a branded topical antiviral underwent reformulation or extension strategies. Where the underlying active ingredient is old, the estate is usually thinner, and generic entry tends to proceed via formulation redesign plus non-infringing regulatory positioning.

How many patents cover D06BB antivirals, and what is the typical strength profile by claim type?

Answer: “How many” is activity-dependent, but the typical pattern is a small number of substance patents plus a larger set of formulation and method-of-use publications. Strength is usually highest for composition-of-matter that is directly tied to a specific concentration range and excipient system and for method claims with clear clinical endpoints.

Strength profile by claim type (typical D06BB pattern)

Substance (API or salt/polymorph): Highest legal leverage; tends to block both direct generics and many “drop-in” formulations.
Formulation (composition claims): Medium to high leverage if ranges and excipients are specific and supported by examples and stability data.
Method-of-use: Medium leverage; often litigated through infringement-by-regimen theories, but subject to prior art and medical-use eligibility rules by jurisdiction.
Process/manufacturing: Usually medium leverage; can be circumvented by switching production routes if claims are not product-by-process.

When do ATC D06BB antiviral patents expire, and what drives the exclusivity calendar?

Answer: Expiry timing is driven by the last priority date of the newest filing cluster, then extended (in select jurisdictions) by SPCs and regulatory data/market exclusivity where available. For topical D06BB antivirals, the exclusivity calendar often consists of staggered formulation patents rather than a single “cliff.”

The typical D06BB timeline pattern

Early substance filings: Often 1990s-2010s.
Reformulation wave: 5 to 15 years after initial launch (new vehicles, improved stability).
Use/range optimization filings: Usually mid-life.
Late-stage lifecycle IP: Packaging, patient compliance systems, or specific regimen claims.

What matters to market entry timing

Orange Book-type exclusivity is relevant only where an NDA includes listed drugs. For topicals, the regulatory status often sits in ANDA territory, but listings vary.
For patent expiry strategy, generics focus on:
- Skin-symptom endpoints that are not tied to the claimed method regimen.
- Vehicle changes to avoid exact composition coverage.
- New pH and stabilizer systems to exit formulation claim boundaries.

What is the Orange Book status of ATC Class D06BB antivirals, and how many NDAs list relevant patents?

Answer: Orange Book coverage depends on whether the product is approved under an NDA and lists patents for that specific strength/dosage form. For D06BB, many actives are marketed under multiple NDA/ANDAs across countries, and US patent listings are product-specific.

Featured snippet: how to interpret Orange Book for D06BB

Listed patents that end the soonest define the “Paragraph IV window” for ANDA filers.
Formulation patents are frequently listed against the dosage form, not the API alone.
Method-of-use patents may list for specific indications or treatment regimens if the label contains the covered use.

Which companies hold the patent estates for D06BB antivirals?

Answer: The estate holders vary by active ingredient and brand. The dominant pattern in D06BB is:

Brand originators owning early substance filings and initial formulation IP
Lifecycle companies owning reformulation patents after mergers or licensing
Local generics owning formulation alternatives in jurisdictions with weaker or later-lived enforcement

How the estate ownership usually maps commercially

Originator: API and initial topical formulation
Licensees or affiliates: reformulations and jurisdiction-specific follow-ons
Generic entrants: typically do not own major blocking patents; they file around and challenge listed patents where permitted

Which generic entry risks exist for ATC D06BB antivirals, and where do ANDA Paragraph IV challenges concentrate?

Answer: Paragraph IV challenges concentrate on products with (1) listed formulation patents with narrow concentration/range definitions, and (2) method-of-use patents that overlap label language. Generic entry risk is lower where the brand has broad composition coverage or multiple staggered formulation patents listed against the same dosage form.

Generic entry risk drivers

Vehicle-dependent composition coverage: If the brand’s formulation claims require specific excipients and concentration ranges, generics can redesign vehicles.
Stability and pH limitations: New systems can avoid literal infringement but must still pass bioequivalence and quality.
Regimen-specific method-of-use: If label language tracks the claim language, infringement risk increases.

Typical Paragraph IV playbook for topical antivirals

File with a carved label that removes the covered regimen language (where feasible).
Claim non-infringement through formulation redesign.
Argue invalidity on obviousness or lack of novelty using earlier topical antiviral disclosures.

What patent litigation affects ATC D06BB antivirals, and what settlement patterns are common?

Answer: Topical antiviral litigation typically targets formulation and method-of-use patents rather than the base API. Settlement patterns in this category usually include:

Agreed launch dates (delayed generic entry)
Carve-outs for dosage forms or strengths not directly covered by the asserted patents
Injunction risk in early settlements if patents are construed broadly

Litigation hotspots

Jurisdictions with active patent enforcement and rapid court timelines
US for ANDA-driven listed patents
EU where SPCs or EP-family claim scopes extend exclusivity

How does ATC D06BB patent coverage compare with systemic antivirals (ATC J05) for competitive advantage?

Answer: D06BB topical antivirals often have narrower market size and fewer regulatory incentives for reformulation, but the IP barrier can be higher per unit of product because formulation and regimen patents are easier to claim around and then hard to litigate precisely. Systemic antivirals often face broader, earlier-expiring substance estates plus extensive bioequivalence precedent; topical products face vehicle-specific claim drafting.

Competitive consequence

Systemic: stronger substance-driven IP in many classes
Topical D06BB: stronger formulation-driven IP in many products

What formulations are protected by D06BB antiviral patents (cream, gel, solution, ointment)?

Answer: Patents most often protect:

Semi-solid creams and gels with specific polymer matrices and rheology modifiers
Alcohol-containing topical gels (for skin penetration) with defined solubilizer systems
Ointment bases with emollient compositions for sustained contact time
Solutions/sprays where claims target solvent ratios, viscosity, and stabilizer packages

Dosage form-specific risk

If the patented claims specify the dosage form vehicle, a generic can reduce risk by using a different vehicle category.
If the claims tie API concentrations to excipient identities, risk persists even when switching from cream to gel if the claim language remains broad enough.

What method-of-use patents cover D06BB antivirals, and how do they affect label design?

Answer: Method-of-use claims in D06BB typically cover topical application timing and frequency for treating specific skin manifestations. These can impact label design because the label language can be used as evidence of infringement.

Typical regimen claim elements

Application frequency (for example, multiple daily doses)
Treatment duration thresholds (days)
Timing relative to lesion onset (early intervention)
Patient subset restrictions

Practical label strategy for challengers

Avoid explicit regimens that match claim language
Use general language consistent with a non-infringing application pattern where allowed by regulators

Which jurisdictions have the strongest patent enforcement for D06BB antivirals, and why?

Answer: Enforcement strength depends on claim quality, local injunctive standards, and availability of supplementary protection. For D06BB:

Countries with robust injunction practices and consistent patent construction increase deterrence.
Jurisdictions allowing SPC or equivalent extension for topicals can extend enforcement of formulation and use patents tied to marketing authorizations.

Where companies focus enforcement

US (listed patents and ANDA litigation)
Selected EU states with reliable patent litigation throughput
UK and other major common-law systems where injunction and damages frameworks are familiar

How do licensing deals shape the D06BB competitive landscape?

Answer: Licensing is common where the originator holds the core formulation but lifecycle improvements are owned by different entities. License structures can include:

Co-development for reformulated topicals
Patent cross-licenses where vehicle patents overlap
Distribution licensing after exclusivity but before generic entry

What licensing changes for investors and litigators

Who is the true plaintiff/defendant in litigation
Which patents are “active” versus dormant portfolio assets
Whether a settlement requires mutual freedom-to-operate arrangements

What FDA regulatory milestones matter for D06BB antiviral generic competition?

Answer: For US competition dynamics, milestones are anchored in:

ANDA submission timing relative to listed patent expiry
Patent certification (Paragraph IV) decisions
Approval and launch gating relative to any 30-month stay and settlement dates

Regulatory gating mechanisms for generics

30-month stay following a Paragraph IV filing (if applicable)
Delayed approval contingent on litigation outcomes
Label design changes that avoid method-of-use infringement theories

Key market dynamics for ATC D06BB antivirals: revenue pressure, payer behavior, and substitution

Answer: D06BB market dynamics are shaped by modest patient counts, episodic usage, and competitive substitution after exclusivity. As generics enter, price and market share compress quickly, while brand differentiation stays tied to (1) formulation acceptability, (2) onset speed claims tied to application technique, and (3) physician familiarity.

What accelerates generic substitution

Strong equivalence perceptions between vehicles at the pharmacy counter
Easy interchangeability across strengths/dosage forms
Label language alignment after regulatory review

What slows substitution

Patent-pending formulation differentiation
Clinical guidance and prescriber preference for specific vehicles
Device or application technique tied to claimed outcomes

Key tables

Table 1. D06BB antiviral patent estate: dominant claim types and typical blocking effect

Claim cluster	Typical patent scope	Blocking effect vs generics	Typical circumvention path
Substance (API/salt/polymorph)	Molecule identity or form	High	Use different form if permitted; wait expiry
Formulation composition	Specific concentration and excipients, pH, stabilizers	Medium to high	Redesign vehicle and excipient set; adjust concentration within unclaimed bands
Method-of-use	Application regimen and treatment timing	Medium	Change label/regimen language; argue non-infringement
Process/manufacture	Steps, conditions, parameters	Low to medium	Alternate manufacturing process
Device/packaging (if claimed)	Delivery system and use instructions	Low to medium	Different packaging and administration steps

Table 2. D06BB competition timeline pattern

Phase	Typical duration	Key event	Competitive impact
Launch and early life	0-5 years	Substance + initial formulation filings dominate	Brand holds leverage; few challenges
Midlife reformulation	5-15 years	Vehicle and stability patents accumulate	Generic risk shifts to formulation bundles
Late lifecycle	10-20 years	Method-of-use/regimen and range refinement	Label and vehicle redesign become main strategy
Post-expiry	after last listed patent expiry	Generic entry or therapeutic equivalence	Rapid price compression

Table 3. Litigation and settlement: common outcomes in topical antivirals

Outcome	Typical terms	How it affects generic launch
Settlement with agreed launch date	Brand receives delayed entry; generic gets launch window	Entry occurs at date agreed, sometimes with design carve-outs
Narrow settlement by dosage form	Claims limited to specific strengths/vehicles	Generic may launch for other forms earlier
Licensing-based resolution	Co-existence via licensing	Delays or enables entry depending on license terms
Court decision on infringement/validity	Injunction or invalidation	Determines immediate launch feasibility

Key Takeaways

D06BB antiviral patent estates typically split across formulation composition and method-of-use rather than relying on broad, single substance patents.
Market dynamics track patent stagger points driven by reformulation and regimen refinement, not just the earliest substance filing.
Generic entry risk rises where Orange Book listings (US) or local family claim scopes tie to both the dosage form and label regimen.
Litigation and settlements in this category usually target vehicle-specific and regimen-specific patents, with launch dates and product carve-outs as the core settlement mechanics.

FAQs

What patent families most often block generic cream or gel versions of D06BB topical antivirals?
How do method-of-use patents for topical herpes antivirals influence label wording and substitution at the pharmacy?
What role do formulation stability and pH control patents play in infringement claims for topical antivirals?
When do D06BB topical antivirals become eligible for US generic entry relative to listed patent expiry and any 30-month stay?
Which excipient and vehicle changes most reliably reduce infringement risk for formulation patents in ATC D06BB?

References

European Medicines Agency (EMA). (n.d.). European patent and SPC guidance and regulatory exclusivity materials. European Medicines Agency.
FDA. (n.d.). Drugs@FDA database and Orange Book listings guidance. U.S. Food and Drug Administration.
FDA. (n.d.). Hatch-Waxman regulatory framework and 30-month stay overview. U.S. Food and Drug Administration.
World Intellectual Property Organization (WIPO). (n.d.). Patent law and enforcement resources. WIPO.